1.1
Zolbetuximab with fluoropyrimidine- and platinum-based chemotherapy is not recommended, within its marketing authorisation, for untreated, locally advanced, unresectable or metastatic, claudin-18.2-positive, HER2-negative, gastric or gastro-oesophageal junction adenocarcinoma in adults.